Hyperimmune intravenous immunoglobulin (hIVIG) added to standard of care, including remdesivir, did not seem to be helpful in improving clinical outcomes in hospitalized patients with severe COVID-19, suggests a randomized trial published in the Lancet.

Patients who received hIVIG did not appear to have better odds of a better clinical outcome at day 7 in comparison with those who received placebo (adjusted OR 1.06). Composite safety results were similar between hIVIG and placebo groups at day 28 (HR 0.79), noted the researchers. Additionally, adverse event risk was higher in those receiving hIVIG who were antibody-positive (26.3% vs. 16.4%; OR 2.21) while it was lower in those who were antibody-negative (22.7% vs. 34.3%; OR 0.51)… (Medpage Today)